CEO Says Strength Of R&D Arm Made Glenmark Buck Spinoff Trend (India)
This article was originally published in PharmAsia News
The CEO of Glenmark Pharmaceuticals says his Indian company decided to spin off its generics business rather than its research and development operations, as is the norm, because R&D is the core of its business. Glenn Saidanha said he felt the R&D work could not be sustained on its own and saw no reason to keep it independent. His Indian competitors tend to spin off R&D work in an attempt to increase their funds, but Saidanha said Glenmark already had strong assets providing it with returns before its products go on the market. He also said Glenmark is in the market for small acquisition deals to add to its vertical integration. (Click here for more
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.